Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reward Circuit Dysfunction in MDD
NCT03148522Unknown
- Sponsor
- Peking University
- Start
- Jun 2017
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of escitalopram, duloxetine and mirtazapine in major depressive disorder (MDD) (3 arms), sponsored by Peking University. Primary endpoint: Hamilton Rating Scale for Depression at 8 weeks. Status: unknown.
02
Drugs
escitalopramduloxetinemirtazapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03148522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03148522.